Image3_A Circ-0007022/miR-338-3p/Neuropilin-1 Axis Reduces the Radiosensitivity of Esophageal Squamous Cell Carcinoma by Activating Epithelial-To-Mesenchymal Transition and PI3K/AKT Pathway.TIF
Radiotherapy resistance is an important cause of treatment failure in esophageal squamous cell carcinoma (ESCC). Circular RNAs have attracted a lot of attention in cancer research, but their role in ESCC radiosensitivity has not been elucidated yet. Here, we aimed to evaluated the functional impacts of circ-0007022 on ESCC radiosensitivity. In this study, a stable radiotherapy-resistant cell line was established and verified by a series of functional experiments. Subsequently, high-throughput sequencing revealed that circ-0007022 was significantly overexpressed in the radiotherapy-resistant cell line and this conclusion was verified in ESCC patients’ tumor tissues by real-time quantitative PCR. Moreover, loss-of-function and overexpression experiments in vitro and in vivo revealed that, after irradiation, the abilities of proliferation and migration in circ-0007022-overexpressing stable transgenic strain were significantly higher than that in circ-0007022-knockdown stable transgenic strain. Additionally, RNA Immunoprecipitation, RNA pull-down, luciferase reporter assays, and fluorescence in situ hybridization experiments demonstrated the mechanism of how circ-0007022 could sponge miR-338-3p and upregulate downstream target of miR-338-3p, neuropilin-1 (NRP1). Moreover, NRP1 led to poor prognosis for ESCC patients receiving radiotherapy, and NRP1 knock-down enhanced radiosensitivity of ESCC cells. Furthermore, circ-0007022 overexpression activated Epithelial-to-mesenchymal transition and PI3K/Akt pathway, and NRP1 knock-down could reversed this phenomenon. Finally, Akt Inhibitor reversed circ-0007022s role in radiotherapy in ESCC cells. Taken together, the circ-0007022/miR-338-3p/NRP1 axis enhances the radiation resistance of ESCC cells via regulating EMT and PI3K/Akt pathway. The new circRNA circ-0007022 is thus expected to be a therapeutic target for ESCC patients.
History
References
- https://doi.org//10.1038/s41388-020-01530-6
- https://doi.org//10.6004/jnccn.2019.0033
- https://doi.org//10.1042/CS20190990
- https://doi.org//10.1016/j.canlet.2020.01.022
- https://doi.org//10.3892/ijo.2018.4451
- https://doi.org//10.7150/jca.56123
- https://doi.org//10.3390/cancers12123582
- https://doi.org//10.3892/ijo.2019.4938
- https://doi.org//10.1002/mc.22990
- https://doi.org//10.1111/jcmm.12623
- https://doi.org//10.1093/eurheartj/ehw001
- https://doi.org//10.1186/s12943-018-0936-4
- https://doi.org//10.1186/s12957-021-02234-1
- https://doi.org//10.1038/s41568-020-00306-0
- https://doi.org//10.3389/fcell.2018.00020
- https://doi.org//10.1038/280339a0
- https://doi.org//10.1186/s12943-019-1095-y
- https://doi.org//10.3389/fonc.2020.01612
- https://doi.org//10.2147/CMAR.S273826
- https://doi.org//10.1186/s13046-016-0291-5
- https://doi.org//10.1038/s41419-020-2607-9
- https://doi.org//10.1038/cr.2015.82
- https://doi.org//10.7150/thno.19353
- https://doi.org//10.1177/0963689720963948
- https://doi.org//10.1111/1759-7714.13397
- https://doi.org//10.18632/aging.102580
- https://doi.org//10.1038/s41419-018-1287-1
- https://doi.org//10.1016/j.omtn.2021.02.023
- https://doi.org//10.1186/s12935-019-0963-2
- https://doi.org//10.1016/j.lfs.2020.118168
- https://doi.org//10.1093/annonc/mdx279
- https://doi.org//10.1080/15476286.2018.1486659
- https://doi.org//10.21769/BioProtoc.2253
- https://doi.org//10.1016/j.cell.2011.07.014
- https://doi.org//10.1111/cas.14511
- https://doi.org//10.23736/S0026-4806.19.06251-7
- https://doi.org//10.1038/s41419-018-0611-0
- https://doi.org//10.3322/caac.21660
- https://doi.org//10.1016/j.omtn.2020.11.018
- https://doi.org//10.1186/s13578-018-0252-0
- https://doi.org//10.18632/aging.102576
- https://doi.org//10.1038/s41419-021-03977-1
- https://doi.org//10.3892/etm.2021.9996
- https://doi.org//10.1111/1759-7714.14221
- https://doi.org//10.1016/j.jhep.2018.01.012
- https://doi.org//10.1080/2162402X.2016.1185582
- https://doi.org//10.7150/thno.48264
- https://doi.org//10.1002/ijc.31329
- https://doi.org//10.1016/j.ymthe.2017.06.009
- https://doi.org//10.1038/s41419-021-03911-5
Usage metrics
Read the peer-reviewed publication
Categories
- Gene and Molecular Therapy
- Gene Expression (incl. Microarray and other genome-wide approaches)
- Genetics
- Genetically Modified Animals
- Livestock Cloning
- Developmental Genetics (incl. Sex Determination)
- Epigenetics (incl. Genome Methylation and Epigenomics)
- Biomarkers
- Genomics
- Genome Structure and Regulation
- Genetic Engineering
CC BY 4.0